hers weight loss glp-1 reviews Despite the Stigma, Hims & Isn't Backing Away From Weight-Loss Drugs Hims & @Hers sees strong
Description
Author contributions Andr J
Anxiety has emerged as a reported side effect in some patients taking semaglutide, affecting approximately 5-8% of users in real-world data
doi: 10.1038/s41386-019-0384-x
This was the partners second try for FDA approval after the regulator rejected Ngenlas first bid in January 2022
however, direct data linking GLP-1 signaling to improved healthspanthrough measures such as physical function, frailty indices, cognition, or time-to-disabilityremain limited in humans
The slowed gastric emptying may also reduce oral intake, as patients feel fuller longer and may struggle to consume adequate fluids
